ZAI LAB LIMITED Authorized Dilution
Share-issuance capacity and approved equity plans, with the disclosed share class, period, approval and expiry. Gross charter headroom is authorized minus issued shares, not a forecast. Equity plan reserves may use weighted counting rules, overlap charter capacity, and must not be added to it. Outstanding awards, future grants, and proposed approvals are distinct. * denotes calculated capacity.
| As of | Authorization / plan | Share class | Authorized / approved limit (shares) | Issued shares / outstanding awards (shares) | Remaining capacity (shares / reserve units) | Approval status | Approval date | Expiry / conditions | Basis / limitations | Source |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |